In Vitro and In Vivo Models for Analysis of Resistance to Anticancer Molecular Therapies

The efficacy of classical and molecular therapies in cancer is hampered by the occurrence of primary (intrinsic) and secondary (acquired) refractoriness of tumours to selected therapeutic regimens. Nevertheless, the increased knowledge of the genetic, molecular and metabolic mechanisms underlying cancer results in the generation of a correspondingly increasing number of druggable targets and molecular drugs. Thus, a current challenge in molecular oncology and medicinal chemistry is to cope with the increased need for modelling, both in cellular and animal systems, the genetic assets associated to cancer resistance to drugs. In this review, we summarize the current strategies for generation and analysis of in vitro and in vivo models, which may reveal useful to extract information on the molecular basis of intrinsic and acquired resistance to anticancer molecular agents.

[1]  Wei Wang,et al.  Transient PI3K Inhibition Induces Apoptosis and Overcomes HGF-Mediated Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer , 2011, Clinical Cancer Research.

[2]  Pallu Reddanna,et al.  Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: role of COX-2 and MDR-1. , 2008, Leukemia research.

[3]  Joshua J. Steffan,et al.  The Green Tea Polyphenol EGCG Potentiates the Antiproliferative Activity of c-Met and Epidermal Growth Factor Receptor Inhibitors in Non–small Cell Lung Cancer Cells , 2009, Clinical Cancer Research.

[4]  Marc Peeters,et al.  Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  G. Tortora,et al.  Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Human Cancer Cells with Acquired Resistance to Antiepidermal Growth Factor Receptor Therapy , 2004, Clinical Cancer Research.

[6]  G. Fuh,et al.  Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells , 2007, Nature Biotechnology.

[7]  R. Bernards,et al.  Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR , 2012, Nature.

[8]  Douglas Hanahan,et al.  Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy , 2010, Proceedings of the National Academy of Sciences.

[9]  A. Rossi,et al.  The role of antiangiogenetic agents in the treatment of breast cancer. , 2011, Current Medicinal Chemistry.

[10]  J. Eberwine,et al.  Mammalian cell transfection: the present and the future , 2010, Analytical and bioanalytical chemistry.

[11]  G. Tortora,et al.  Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy. , 2007, Differentiation; research in biological diversity.

[12]  C. Grütter,et al.  Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR. , 2008, Bioorganic & medicinal chemistry.

[13]  J. Isola,et al.  Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. , 2005, Cancer research.

[14]  Claudia d’Amato,et al.  Sphingosine Kinase 1 Overexpression Contributes to Cetuximab Resistance in Human Colorectal Cancer Models , 2012, Clinical Cancer Research.

[15]  Michael B Atkins,et al.  Resistance to targeted therapy in renal-cell carcinoma. , 2009, The Lancet. Oncology.

[16]  Violeta Serra,et al.  Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. , 2008, Cancer research.

[17]  A. Harris,et al.  DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. , 2011, Cancer research.

[18]  A. Bardelli,et al.  Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. , 2010, JAMA.

[19]  R. Birge,et al.  Sphingosine kinase 1 overexpression is regulated by signaling through PI3K, AKT2, and mTOR in imatinib-resistant chronic myeloid leukemia cells. , 2011, Experimental hematology.

[20]  Gabriele Bergers,et al.  Modes of resistance to anti-angiogenic therapy , 2008, Nature Reviews Cancer.

[21]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[22]  L. Presta,et al.  Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.

[23]  P. A. Futreal,et al.  Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. , 2010, Cancer research.

[24]  G. Mills,et al.  Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition , 2011, Oncogene.

[25]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[26]  A. Bardelli,et al.  Toll-like Receptor 9 Agonist IMO Cooperates with Cetuximab in K-Ras Mutant Colorectal and Pancreatic Cancers , 2011, Clinical Cancer Research.

[27]  D. Zecchin,et al.  Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses , 2008, Proceedings of the National Academy of Sciences.

[28]  A. Rossi,et al.  The role of EGFR tyrosine kinase inhibitors in the first-line treatment of advanced non small cell lung cancer patients harboring EGFR mutation. , 2012, Current medicinal chemistry.

[29]  E. Pérez-Payá,et al.  Intrinsic caspase-8 activation mediates sensitization of erlotinib-resistant tumor cells to erlotinib/cell-cycle inhibitors combination treatment , 2012, Cell Death and Disease.

[30]  S. Cook,et al.  Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY‐142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines , 2009, International journal of cancer.

[31]  Jingyi Zhang,et al.  Myc induced miR-144/451 contributes to the acquired imatinib resistance in chronic myelogenous leukemia cell K562. , 2012, Biochemical and biophysical research communications.

[32]  N. Ferrara,et al.  Refractoriness to antivascular endothelial growth factor treatment: role of myeloid cells. , 2008, Cancer research.

[33]  G. Tortora,et al.  Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy. , 2005, Endocrine-related cancer.

[34]  L. Ellis,et al.  Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology , 2009, Clinical Cancer Research.

[35]  Hua Guo,et al.  Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways , 2011, Nature Medicine.

[36]  S. Ramaswamy,et al.  Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.

[37]  Mingming Jia,et al.  COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer , 2010, Nucleic Acids Res..

[38]  T. Efferth.  Signal transduction pathways of the epidermal growth factor receptor in colorectal cancer and their inhibition by small molecules. , 2012, Current medicinal chemistry.

[39]  Bin Fang,et al.  A chemical and phosphoproteomic characterization of dasatinib action in lung cancer , 2010, Nature chemical biology.

[40]  A. Scaloni,et al.  Increased anaerobic metabolism is a distinctive signature in a colorectal cancer cellular model of resistance to antiepidermal growth factor receptor antibody , 2013, Proteomics.

[41]  G. Mills,et al.  Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors , 2003, Oncogene.

[42]  J. Doherty,et al.  NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. , 1998, Cancer research.

[43]  A. Bardelli,et al.  Isogenic mutant human cells: A new tool for personalized cancer medicine , 2010, Cell cycle.

[44]  Ming Tan,et al.  PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. , 2004, Cancer cell.

[45]  A. Richmond,et al.  Mouse xenograft models vs GEM models for human cancer therapeutics , 2008, Disease Models & Mechanisms.

[46]  Kam Y. J. Zhang,et al.  Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma , 2010, Nature.

[47]  M. Kurosumi,et al.  Isolation and characterization of a new human breast cancer cell line, KPL-4, expressing the Erb B family receptors and interleukin-6 , 1999, British Journal of Cancer.

[48]  Francesca Molinari,et al.  Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. , 2010, The Journal of clinical investigation.

[49]  W. Pao,et al.  How genetically engineered mouse tumor models provide insights into human cancers. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  C. Croce,et al.  EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers , 2011, Nature medicine.

[51]  J. Sun,et al.  EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers , 2011, Nature Medicine.

[52]  O. Merimsky,et al.  Combining an EGFR directed tyrosine kinase inhibitor with autophagy-inducing drugs: a beneficial strategy to combat non-small cell lung cancer. , 2011, Cancer letters.

[53]  R. Nasr,et al.  Eradication of acute promyelocytic leukemia-initiating cells by PML/RARA-targeting , 2010, International journal of hematology.

[54]  A. Ryan,et al.  Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Anti–Epidermal Growth Factor Receptor Drugs in Human Cancer Cells , 2008, Clinical Cancer Research.

[55]  Davide Corà,et al.  A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. , 2011, Cancer discovery.

[56]  T. Efferth,et al.  Inhibition of tumor angiogenesis by antibodies, synthetic small molecules and natural products. , 2011, Current medicinal chemistry.

[57]  D. Melisi,et al.  Anti-VEGF Treatment–Resistant Pancreatic Cancers Secrete Proinflammatory Factors That Contribute to Malignant Progression by Inducing an EMT Cell Phenotype , 2011, Clinical Cancer Research.

[58]  C. Croce,et al.  microRNA involvement in human cancer. , 2012, Carcinogenesis.

[59]  M. Stratton,et al.  Abstract 2206: Genomics of Drug Sensitivity in Cancer (GDSC): A resource for therapeutic biomarker discovery in cancer cells. , 2013 .

[60]  D. Gerber,et al.  Targeted therapies: a new generation of cancer treatments. , 2008, American family physician.

[61]  Enzo Medico,et al.  Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer , 2012, Nature.

[62]  S. Orsulic,et al.  Mouse models of cancer. , 2011, Annual review of pathology.

[63]  Lewis C Cantley,et al.  The APL paradigm and the "co-clinical trial" project. , 2011, Cancer discovery.

[64]  Kazuko Sakai,et al.  Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK–Positive Non–Small Cell Lung Cancer , 2012, Clinical Cancer Research.

[65]  T. Fojo,et al.  Biologically Targeted Cancer Therapy and Marginal Benefits: Are We Making Too Much of Too Little or Are We Achieving Too Little by Giving Too Much? , 2010, Clinical Cancer Research.

[66]  J. Minna,et al.  Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. , 2006, Journal of the National Cancer Institute.

[67]  E. Schenborn,et al.  DEAE-dextran transfection of mammalian cultured cells. , 2000, Methods in molecular biology.

[68]  N. Sion-Vardy,et al.  EML4-ALK-positive non-small cell lung cancer in a patient treated with azathioprine for ulcerative colitis. , 2012, Tumori.

[69]  Sridhar Ramaswamy,et al.  Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells , 2012, Nucleic Acids Res..

[70]  Andrew L. Kung,et al.  A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response , 2012, Nature.

[71]  P. Jänne,et al.  Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer , 2008, Clinical Cancer Research.

[72]  Jorma Isola,et al.  Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. , 2004, Molecular cancer therapeutics.

[73]  A. Friedman,et al.  Resistance to Tyrosine Kinase Inhibition by Mutant Epidermal Growth Factor Receptor Variant III Contributes to the Neoplastic Phenotype of Glioblastoma Multiforme , 2004, Clinical Cancer Research.

[74]  Vivienne Marsh,et al.  Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor , 2007, Clinical Cancer Research.